72148
document
Brief Report : Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate : Week 144 Results . BACKGROUND Cobicistat ( COBI ) is a pharmacoenhancer with no antiretroviral activity . METHODS International , randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir ( RTV ) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144 . RESULTS At Week 144 , virologic suppression was achieved in 72 % ( COBI ) and 74 % ( RTV ) of patients . Adverse events leading to study drug discontinuation occurred in 11 % of patients in each group . Median changes in serum creatinine ( mg/dL ) were +0.13 ( COBI ) and +0.07 ( RTV ) and were unchanged from week 48 . CONCLUSIONS Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir .
72149
Intervention_Pharmacological
Cobicistat
72150
Intervention_Pharmacological
Ritonavir
72151
Intervention_Pharmacological
Atazanavir
72152
Intervention_Pharmacological
Combination With Emtricitabine/Tenofovir Disoproxil Fumarate
72153
Intervention_Pharmacological
Cobicistat
72154
Intervention_Pharmacological
COBI
72155
Intervention_Pharmacological
ritonavir ( RTV )
72156
Intervention_Pharmacological
atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate
72157
Intervention_Pharmacological
COBI
72158
Intervention_Pharmacological
RTV
72159
Intervention_Pharmacological
COBI
72160
Outcome_Other
efficacy and safety
72161
Outcome_Physical
virologic suppression
72162
Outcome_Adverse-effects
Adverse events
72163
Outcome_Physical
changes in serum creatinine
72164
Participant_Condition
HIV treatment-naive patients